PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

FDA slaps partial hold on Curis leukemia study

Curis’ phase 1/2a leukaemia study is the latest to join the club of FDA clinical holds, following the death of a trial participant.

The Massachusetts-based biotech announced the partial clinical hold today, citing the FDA’s request for additional safety and efficacy data, including more information about the patient death.

The trial on pause is TakeAim Leukemia, which is studying different doses of orally-administered emavusertib — an IRAK4 kinase inhibitor — as monotherapy in combination with azacitidine or venetoclax for patients with relapsed or refractory acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome.

After a patient in the study died as a result of multiple conditions, one of them being rhabdomyolysis, the FDA is asking Curis to pause enrollment of new participants. Rhabdomyliosis is the breakdown of muscle and is a known side effect of high doses of emavusertib.

“Given the clinical profile of emavusertib observed to date, we are hopeful that the study can be resumed soon, after appropriate review,” Curis CEO James Dentzer said in a statement. Curis will share an update on the timing of talks about a path to market for emavusertib once the impact of the hold on the trial is clearer.

Grade 3 rhabdomyolysis cases have been observed at the 300-mg, 400-mg and 500-mg doses of the drug. The company chose 300 mg as the phase 2 dose.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026